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OBJECTIVE: The Turkish health care system is increas-
ingly pressured by costs. In 1980 total health expendi-
tures were 2.1 billions of dollars and in 2000, 8.2 billion
dollars. In the present study, we aimed to analyze health
insurance system and inpatient expenditures for diabetic
prescription drugs. People in Turkey are covered by four
different health insurance systems. 1) Emekli Sandigi: re-
tirement foundation for the government employees. 2)
Sosyal Sigortalar Kurumu: social security system for la-
borers. 3) Bag-Kur: governmental free security system. 4)
Private insurance companies that cover health care. All
these social security systems, namely the government, pay
90–100% of both inpatient and outpatient prescriptions,
whereas in other countries this is not the case. Although
Turkey is living with a high rate inflation, our country
has been spending increasing amounts on health care
most of which is reimbursement. However, since there
are scarce number of pharmacoeconomic studies, an esti-
mation cannot be made. METHODS: Numune Hospital
is the biggest governmental hospital with a 1453 active
bed capacity. We analyzed prospectively prescription
costs per diabetic patient from January between Decem-
ber 2000 at Endocrinology and Diabetes Inpatient Unit.
RESULTS: Our results revealed that 122.69 dollars are
paid per patient. This cost does not include the other
treatment costs or the hospital expenditures, it is the
amount paid per patient for drugs. CONCLUSIONS: For
the inpatients, we know that the treatment and prescrip-
tion is rational. On the other hand our previous research
revealed polypharmacy and irrational drug use is a seri-
ous problem for outpatients. We therefore conclude that
pharmacoeconomic studies should be encouraged and
used to evaluate health costs.
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INTRODUCTION: Otitis media and acute otitis media
(AOM) are the most common diseases among children in
the US with an annual cost of more than $3 billion in
1996. Historically, a ten-day course of antibiotics has
been the standard treatment for AOM. Providers can
choose first-line antibiotics (Amoxicillin, Trimethoprim-
Sulfamethoxazole, and Erythromicin-Sulfisoxazole) or a
group of second-line antibiotics. Second-line antibiotics
generally have a broader spectrum of activity but are
more costly relative to first-line antibiotics. Presently,
policy-makers have little evidence to evaluate the in-
creased effectiveness of second-line antibiotics for AOM
in practice. OBJECTIVES: As a first step to address this
question, this study describes the factors related to the
choice between first-line and second-line antibiotics for
initial AOM in Iowa Medicaid population. METHODS:
We identified 19,987 Iowa Medicaid eligible children less
than 13 year of age who had initial AOM from 1990
through 1997. We estimated the probability of the sec-
ond-line agent use across the patient demographics (age,
sex), previous antibiotic use, year of diagnosis, patient’s
county, and the specialty of the treating physician. RE-
SULTS: Factors of age (p  0.01), county (p  0.01),
previous antibiotic use (p  0.01), provider specialty
(p  0.01), and year of diagnosis (p  0.01) had statisti-
cally significant effects on second-line prescribing. We
found that second-line prescribing increased over time.
With respect to specialty, general practitioners (OR 
1.33, 95% CI  1.18–1.49), family practitioners (OR 
1.10, 95% CI  1.01–1.19), and otolaryngologists
(OR  1.83, 95% CI  1.53–2.18) were more likely to
prescribe second-line antibiotics than pediatricians. In
addition, the effect of the timing of previous antibiotic
use on second-line prescribing varied with type of antibi-
otic previously used. Any second-line antibiotic used
within the last 180 days was positively related to second-
line antibiotic use for initial AOM. However, only first-
line antibiotic use within the last 60 days contributed to
increased second-line use.
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BACKGROUND: Genetic testing for disease predisposi-
tion is rapidly becoming available for a variety of chronic
diseases, but it is not clear how the health insurance in-
dustry will make reimbursement decisions for these new
diagnostics because the long-term clinical and economic
benefits are unclear. A provider of dental health benefits
requested assistance in assessing a genetic test for a com-
posite interleukin-1 (IL-1) genotype. This test is being
marketed to predict risk for progression of periodontal
disease. OBJECTIVE: To estimate the incremental clini-
cal and economic outcomes associated with the use of
IL-1 testing to identify high-risk patients. METHODS: A
disease simulation model was developed using decision-
analytic and Markov modeling techniques over a 30-year
time frame. RESULTS: In the base-case analysis, using
